NINTEDANIB AND PIRFENIDONE AFFECT GROWTH AND DIFFERENTIATION OF HUMAN ALVEOLAR TYPE 2 CELLS

This study demonstrates that while both pirfenidone and nintedanib enhance the growth of human alveolar type 2 (AT2) cell organoids, nintedanib uniquely preserves their AT2-like differentiation state and surfactant protein C expression, suggesting it acts proximal to TGF-beta signaling.

The Gist

The Big Picture: A Broken Construction Site

Imagine your lungs are a bustling city. The most important workers in this city are the Alveolar Type 2 (AT2) cells. Think of them as the master builders or foremen. Their job is twofold:

1. They produce a special "foam" (surfactant) that keeps the air sacs from collapsing.
2. When the city gets damaged, they repair themselves and turn into Type 1 cells (the thin, glass-like walls needed for breathing).

In a disease called Idiopathic Pulmonary Fibrosis (IPF), the city is under attack. The master builders (AT2 cells) get tired, old, and confused. Instead of fixing the walls, they panic and turn into something weird: abnormal "basaloid" cells. These are like construction workers who have forgotten how to build houses and are instead just piling up bricks (scar tissue) everywhere. This turns the soft, spongy lung into a hard, stiff brick wall, making it impossible to breathe.

Doctors have two main drugs to slow this down: Pirfenidone and Nintedanib. But until now, nobody knew exactly how they helped the master builders. This study tried to figure that out.

---

The Experiment: A Mini-Lung in a Dish

The researchers took lung cells from people with healthy lungs and people with IPF. They put these cells in a 3D "soup" (a gel) to grow little mini-lungs called organoids.

They split the groups into four:

1. No Drug: The control group.
2. Pirfenidone: One of the standard drugs.
3. Nintedanib: The other standard drug.
4. TGF-b Inhibitor: A drug that blocks a specific "panic signal" known to cause scarring.

They watched what happened over two weeks.

---

The Results: What the Drugs Did

1. Both Drugs Helped the Builders Multiply

Both Pirfenidone and Nintedanib helped the mini-lungs grow bigger and form more colonies. It was like giving the construction crew a double dose of coffee and energy bars; they started working harder and building more structures.

2. The "Identity Crisis" (The Key Discovery)

Here is where the drugs acted very differently.

• The Control Group (No Drug): The master builders (AT2 cells) got confused. They stopped making their "foam" (a protein called SFTPC) and turned into those weird, scar-making abnormal basaloid cells. The city was turning into a brick wall.
• The Pirfenidone Group: The builders grew in number, but many of them still got confused and turned into the weird scar-making cells. Pirfenidone helped them multiply, but it didn't fully stop them from losing their identity.
• The Nintedanib Group (The Hero): This was the surprise. The builders not only multiplied, but they stayed true to their identity. They kept making their "foam" (SFTPC) and refused to turn into the weird scar-making cells. Nintedanib acted like a loyalty oath, reminding the builders, "You are a master builder! Don't turn into a brick-layer!"

3. The TGF-b Inhibitor (The "Pause Button")

The researchers also tested a drug that blocks the "panic signal" (TGF-b). This drug stopped the builders from turning into the worst kind of scar cells, but it didn't help them stay as healthy master builders either. It was like hitting the "pause" button on the transformation, but the builders were still stuck in a weird middle state.

The Conclusion on Nintedanib: Nintedanib works before the panic signal even gets loud. It stops the transformation at the very beginning, keeping the cells healthy and functional.

---

The Secret Mechanism: The Messenger System

The researchers also looked at the "messenger system" between the builders (epithelial cells) and the support crew (fibroblasts).

• Without Nintedanib: The support crew sends out "panic messages" (signals like collagen and other fibrotic factors) that tell the builders to turn into scar-makers.
• With Nintedanib: The drug changes the support crew's behavior. They stop sending the panic messages and start sending "calm down" messages (like PTN and MDK). It's like the foreman telling the construction crew, "Stop panicking and start building properly."

Interestingly, the study found that Nintedanib didn't just work on the builders directly; it also changed the environment around them to make it safer for them to stay healthy.

---

Why This Matters (The Takeaway)

1. Different Tools for Different Jobs: Even though Pirfenidone and Nintedanib are both used to treat the same disease, they work in different ways. Pirfenidone helps the cells grow, but Nintedanib is better at protecting their identity and stopping them from turning into scar tissue.
2. A New Hope for Other Diseases: Since these drugs help lung cells stay healthy and repair themselves, they might be useful for other lung injuries, like severe cases of COVID-19 or acute lung injury, where the "master builders" are damaged.
3. Personalized Medicine: Because the drugs work differently, some patients might respond better to one than the other. In the future, doctors might be able to test a patient's cells to see which drug will keep their "master builders" happiest.

In short: Nintedanib is like a bodyguard for the lung's repair crew. It doesn't just make them work harder; it protects them from turning into the very thing that destroys the lung (scar tissue), keeping the lungs soft and functional for longer.

Technical Summary

1. Problem Statement

Idiopathic Pulmonary Fibrosis (IPF) is a fatal, progressive lung disease characterized by epithelial cell senescence, loss of alveolar type 2 (AT2) cells, and excessive extracellular matrix deposition. While the drugs pirfenidone and nintedanib are approved to slow IPF progression, their specific mechanisms of action regarding AT2 cell fate, proliferation, and differentiation remain poorly understood. Specifically, it is unclear how these drugs influence the transition of AT2 cells into aberrant basaloid cells (a hallmark of IPF pathology) or how they interact with the TGF-β signaling pathway, which is central to fibrosis.

2. Methodology

The study employed a multi-omics approach using human primary cells and advanced computational biology:

• Cell Models:
  • AT2 Cells: Isolated from normal donor lungs and IPF patient lungs (via lung transplant).
  • Co-culture System: AT2 cells were co-cultured with MRC5 human lung fibroblasts in a 3D organoid system (Matrigel).
  • Treatments: Organoids were treated with pirfenidone, nintedanib, or a TGF-β inhibitor (SB431542) for 14 days.
• Phenotypic Analysis:
  • Colony Formation: Quantification of LysoTracker-positive organoids (indicating AT2 cells with acidic lamellar bodies) using EVOS microscopy and FIJI software.
  • Cell Cycle: Analysis of proliferation stages (S-phase, G2/M, etc.).
• Transcriptomics (scRNA-seq):
  • Single-cell RNA sequencing was performed on dissociated organoids to profile gene expression.
  • Bioinformatics Pipeline:
    • Differential Expression: Pseudo-bulk analysis using limmaVoom.
    • Pathway Analysis: PROGENy for signaling pathway activity; GSEA (Hallmark categories) and fgsea for gene set enrichment.
    • Trajectory Inference: Slingshot to map cellular differentiation trajectories from AT2 to basaloid states.
    • Cell-Cell Communication: CellChat to infer ligand-receptor interactions between fibroblasts (senders) and epithelial cells (receivers).
    • Cell Cycle: Tricycle package for continuous cell cycle annotation.

3. Key Contributions

• Mechanistic Differentiation: The study distinguishes the molecular mechanisms of pirfenidone and nintedanib, showing they act via different pathways despite both increasing AT2 colony formation.
• AT2 Fate Preservation: Demonstrates that nintedanib, but not pirfenidone, preserves the AT2-like transcriptional state (SFTPC+) and prevents differentiation into aberrant basaloid cells.
• Positioning Relative to TGF-β: Establishes that nintedanib acts proximal (upstream) to TGF-β signaling during AT2 differentiation, whereas TGF-β inhibition acts at a later stage.
• Fibroblast-Epithelial Crosstalk: Identifies specific fibroblast-secreted factors (e.g., PTN, MDK) modulated by nintedanib that influence epithelial cell fate.

4. Key Results

A. Phenotypic Effects on Organoids

• Colony Formation: Both pirfenidone and nintedanib significantly increased the number of LysoTracker+ AT2 organoids derived from both normal and IPF donors.
• Colony Size & Structure: Nintedanib-treated organoids were larger and more structured (with luminal spaces) compared to controls.
• Proliferation: Nintedanib treatment resulted in a higher proportion of epithelial cells in the S-phase of the cell cycle compared to controls or pirfenidone.

B. Transcriptional Profiling & Cell Fate

• AT2 Marker Retention (SFTPC):
  • Control & Pirfenidone: Cells largely lost SFTPC expression and acquired a KRT17high/KRT5- "aberrant basaloid" phenotype.
  • Nintedanib: A significant proportion of cells retained SFTPC expression, maintaining an AT2-like state.
  • TGF-β Inhibitor: Cells adopted an intermediate SFTPC-/KRT17low phenotype, distinct from both the nintedanib-treated (AT2-like) and control (basaloid) groups.
• Trajectory Analysis: Slingshot analysis revealed a differentiation trajectory:
  • AT2 (SFTPC+) $\rightarrow$ Intermediate (SFTPC-/KRT17low) $\rightarrow$ Aberrant Basaloid (KRT17high/KRT5-).
  • Nintedanib blocks the transition from the initial AT2 state to the intermediate/basaloid state.
  • TGF-β Inhibition blocks the transition from the intermediate state to the final basaloid state.
• Pathway Analysis:
  • Nintedanib: Downregulated TGF-β, TNF-α/NF-κB, Wnt/β-catenin, p53, and UV response pathways in epithelial cells. It uniquely downregulated PI3K/AKT/mTOR signaling.
  • Pirfenidone: Did not show significant single-gene differential expression but showed pathway-level changes (downregulation of EMT and p53; upregulation of E2F targets).

C. Fibroblast Interaction (CellChat Analysis)

• Nintedanib altered the fibroblast secretome, upregulating pleiotrophin (PTN) and midkine (MDK), and downregulating pro-fibrotic ligands (collagens, PLAU, SEMA5A, POSTN, AREG).
• While TGF-β inhibition shared some effects, nintedanib uniquely downregulated LIF and PI3K pathways in fibroblasts.
• Note: Treating organoids with individual factors (uPAi, LIFi, PTN) did not replicate the nintedanib effect, suggesting a complex, multi-factorial mechanism rather than a single ligand dependency.

5. Significance and Conclusion

• Novel Mechanism of Action: The study suggests that the "antifibrotic" efficacy of nintedanib is partly due to preserving AT2 cell identity and preventing their transdifferentiation into pathological basaloid cells. This is distinct from pirfenidone, which increases colony formation but does not prevent the loss of the AT2 phenotype.
• Therapeutic Implications:
  • Nintedanib acts upstream of TGF-β signaling in the context of AT2 differentiation.
  • The ability of these drugs to enhance AT2 fitness suggests potential utility in other lung diseases characterized by AT2 failure, such as Acute Lung Injury (ALI) or COVID-19 sequelae.
• Personalized Medicine: Since pirfenidone and nintedanib act via different mechanisms on AT2 cells, patient responses may be heterogeneous. Future clinical trials should aim to identify biomarkers to select the appropriate drug for specific patient subgroups.

Limitations: The study relies on a 2-cell type organoid model (AT2 + Fibroblast), lacking endothelial and immune components present in the in vivo lung environment.